NYSEHealth CareHealth Care EquipmentS&P SmallCap 600
$150.87
-1.28 (-0.84%)
Close of Nov 06, 2026 · end-of-day data
TFX 8-K filings in 2025
Every material Form 8-K Teleflex filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Teleflex agreed on December 9, 2025 to sell its OEM business to Lotus US Bidco Inc., an affiliate of Montagu and Kohlberg, for $1.5 billion in cash, and its acute care and interventional urology segments to Intersurgical Limited for $530 million in cash. The company also authorized a share repurchase program of up to $1 billion, which it primarily plans to fund with the sale proceeds, while also intending to pay down debt. Closings are expected in the second half of 2026, subject to regulatory approvals and other conditions.
OEM business sale to Lotus US Bidco Inc. for $1.5 billion in cash, with a $90 million termination fee payable by the buyer under certain circumstances
Acute care and interventional urology segments sold to Intersurgical Limited for $530 million in cash
Board authorized a share repurchase program of up to $1 billion; the company is not required to repurchase shares
Both transactions expected to close in the second half of 2026; outside date September 1, 2026, with extensions possible
Teleflex reported third-quarter 2025 GAAP revenue of $913.0 million, up 19.4%, and a GAAP diluted loss of $(9.24) per share, compared with earnings of $2.36 a year earlier. The loss reflects a $403.9 million non-cash goodwill impairment on its Interventional Urology North America unit, and the company lowered its full-year 2025 GAAP EPS and adjusted constant currency revenue growth outlooks, which matters because the charges and cut weigh directly on reported results.
Q3 GAAP revenue $913.0 million, up 19.4%; adjusted revenue $892.9 million, up 16.8%
Q3 adjusted diluted EPS $3.67 versus $3.49 a year earlier; GAAP diluted EPS $(9.24) versus $2.36
2025 GAAP diluted EPS outlook lowered to $(4.42) to $(4.22) from $6.73 to $7.13; adjusted EPS narrowed to $14.00 to $14.20
Adjusted constant currency revenue growth outlook lowered to 6.90% to 7.40% from 7.70% to 8.70%
Teleflex reported second-quarter 2025 GAAP revenue of $780.9 million, up 4.2% from a year earlier, and GAAP diluted EPS from continuing operations of $2.77, compared with $1.69. The company raised its full-year 2025 guidance, which it says includes the BIOTRONIK Vascular Intervention business acquired at the start of the third quarter. Management said underlying adjusted constant currency revenue guidance, excluding the acquisition, is unchanged.
Adjusted diluted EPS from continuing operations was $3.73, compared with $3.42 in the prior year period; adjusted constant currency revenue growth was 1.0%.
2025 GAAP diluted EPS from continuing operations guidance was raised to $6.73 to $7.13, from $6.51 to $6.91.
2025 adjusted diluted EPS guidance was raised to $13.90 to $14.30, from $13.20 to $13.60.
The acquired BIOTRONIK business is expected to generate $204 million of revenue in the second half of 2025.
On June 24, 2025, Teleflex and certain subsidiaries amended their Third Amended and Restated Credit Agreement to add $200 million of delayed draw term loan commitments, bringing the total to $700 million. The funds become available to draw on the date Teleflex completes its acquisition of the Vascular Intervention business segment of MS Holding II SE, subject to customary conditions. Other terms of the facility were described as substantially unchanged.
Amendment No. 2 dated June 24, 2025, with JPMorgan Chase Bank, N.A. as administrative agent
Additional delayed draw term loan commitments of $200 million, for a total of $700 million
Commitments are available to draw only on the closing date of the pending acquisition of the Vascular Intervention business segment of MS Holding II SE
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Teleflex filing is on SEC EDGAR ↗. 8-K briefs of other companies →